310 / 1068
HIV & ANAL CANCER
•
Wexler et al ( 2007 )
•
32 HIV+ patients treated with CRT ( 5FU+MMC ) between 1997 and 2005
•
Median tumour size 2.8 % ;
44% cT1 cN0
•
5 yr actuarial risk of local failure = 16 %
•
3 / 32 developed distant metastases
•
5 yr overall survival = 65 %
•
5 yr cancer specific survival = 75 %
•
Fraunholz et al ( 2011 )
•
25 HIV + patients and 45 HIV – patients
•
No difference in T or N stage at diagnosis ( all M0 )
•
More young males in the HIV+ group
•
No difference in RT dose delivered
•
72 % HIV+ received full dose of chemotherapy cf. 91 % HIV- group
CR at 8 wks
5 yr local
control
5 yr metastasis
free survival
5 yr overall
survival
HIV +
84 %
65 % 86 %
71 %
HIV -
93 %
pNS
78 %
pNS
91 %
pNS
77 %
pNS